Corina Ratiu

Corina Ratiu

Auto-generated profile, based on publicly available information

Corina Ratiu

German Center of Cardiovascular Research (DZHK), Partner Site Rhein-Main, Frankfurt am Main, Germany

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 March 2021 in Circulation
Verified
Journal Article
Closed access
PDF file
SBSofia-Iris Bibli
Sofia-Iris Bibli
JHJiong Hu
Jiong Hu
MLMario Looso
Mario Looso
Andreas WeigertAndreas Weigert
Andreas Weigert
CRCorina Ratiu
Corina Ratiu
IFIngrid Fleming
Ingrid Fleming
Background: In vascular endothelial cells, cysteine metabolism by the cystathionine γ lyase (CSE), generates hydrogen sulfide–related sulfane sulfur compounds (H 2 S n ), that exert their biological actions via cysteine S -sulfhydration of target proteins. This study set out to map the “ S -sulfhydrome” (ie, the spectrum of proteins targeted by H 2 S n ) in human endothelial cells. Methods: Liquid chromatography with tandem mass spectrometry was used to identify S -sulfhydrated cysteines in endothelial cell proteins and β3 integrin intraprotein disulfide bond rearrangement. Functional studies included endothelial cell adhesion, shear stress–induced cell alignment, blood pressure measurements, and flow-induced vasodilatation in endothelial cell–specific CSE knockout mice and in a small collective of patients with endothelial dysfunction. Results: Three paired sample sets were compared: (1) native human endothelial cells isolated from plaque-free mesenteric arteries (CSE activity high) and plaque-containing carotid arteries (CSE activity low); (2) cultured human endothelial cells kept under static conditions or exposed to fluid shear stress to decrease CSE expression; and (3) cultured endothelial cells exposed to shear stress to decrease CSE expression and treated with solvent or the slow-releasing H 2 S n donor, SG1002. The endothelial cell “ S -sulfhydrome” consisted of 3446 individual cysteine residues in 1591 proteins. The most altered family of proteins were the integrins and focusing on β3 integrin in detail we found that S -sulfhydration affected intraprotein disulfide bond formation and was required for the maintenance of an extended-open conformation of the β leg. β3 integrin S -sulfhydration was required for endothelial cell mechanotransduction in vitro as well as flow-induced dilatation in murine mesenteric arteries. In cultured cells, the loss of S -sulfhydration impaired interactions between β3 integrin and Gα13 (guanine nucleotide-binding protein subunit α 13), resulting in the constitutive activation of RhoA (ras homolog family member A) and impaired flow-induced endothelial cell realignment. In humans with atherosclerosis, endothelial function correlated with low H 2 S n generation, impaired flow-induced dilatation, and failure to detect β3 integrin S -sulfhydration, all of which were rescued after the administration of an H 2 S n supplement. Conclusions: Vascular disease is associated with marked changes in the S -sulfhydration of endothelial cell proteins involved in mediating responses to flow. Short-term H 2 S n supplementation improved vascular reactivity in humans highlighting the potential of interfering with this pathway to treat vascular disease.

25 March 2021 in Blood
Verified
Journal Article
Closed access
PDF file
FLFredy Andrés Delgado Lagos
Fredy Andrés Delgado Lagos
AEAmro Elgheznawy
Amro Elgheznawy
AKAnastasia Kyselova
Anastasia Kyselova
DHDagmar Meyer Zu Heringdorf
Dagmar Meyer Zu Heringdorf
CRCorina Ratiu
Corina Ratiu
IFIngrid Fleming
Ingrid Fleming
Secreted modular calcium binding protein 1 (SMOC1) is an osteonectin/SPARC related matricellular protein, whose expression is regulated by miR-223. Given that platelets are rich in miR-223, this study investigated the expression of SMOC1 and its contribution to platelet function. Both human and murine platelets expressed SMOC1, whereas platelets from SMOC1+/- mice presented no detectable mature SMOC1 protein. Platelets from SMOC1+/- mice demonstrated attenuated responsiveness to thrombin (platelet neutrophil aggregate formation, aggregation, clot formation, Ca2+ increase and β3 integrin phosphorylation), while responses to other platelet agonists were unaffected. SMOC1 has been implicated in TGFb singling but no link to this pathway was detected in platelets. Rather, the SMOC1 kazal domain directly bound thrombin to potentiate its activity in vitro as well as its actions on isolated platelets. The latter effects were prevented by monoclonal antibodies against SMOC1. Platelets from miR-223-deficient mice expressed high levels of SMOC1 and exhibited hyper-reactivity to thrombin that was also reversed by pre-incubation with monoclonal antibodies against SMOC1. Similarly, SMOC1 levels were markedly upregulated in platelets from individuals with type 2 diabetes and the SMOC1 antibody abrogated platelet hyper-responsiveness to thrombin. Taken together, we have identified SMOC1 as a novel thrombin-activating protein that makes a significant contribution to the pathophysiological changes in platelet function associated with type 2 diabetes. Thus, strategies that target SMOC1 or its interaction with thrombin may be attractive therapeutic approaches to normalize platelet function in diabetes.